| Literature DB >> 32323593 |
Kimberly A Koester1, Shana D Hughes1, Robert M Grant1.
Abstract
In the United States, uptake of daily oral pre-exposure prophylaxis (PrEP) to prevent HIV continues to grow albeit at a slower than desired pace. Innovations in PrEP delivery systems may partially address structural challenges related to PrEP uptake and PrEP persistence, such as difficulty in attending clinic visits or completing laboratory testing. To study PrEP services offered by a telehealth company called Nurx, we conducted 31 in-depth interviews with prospective or current patients. We hypothesized that patients would find the quarterly laboratory monitoring requirements to be onerous especially in light of receiving all other aspects of PrEP care through a telehealth delivery system. However, interviewees characterized navigating laboratory systems as relatively easy and complying with the quarterly monitoring as a supplementary benefit of PrEP use. Our research illustrates that quarterly monitoring requirements are meaningful to some telehealth PrEP users and may facilitate persistent engagement in receipt of PrEP care.Entities:
Keywords: PrEP; implementation science; laboratory monitoring; qualitative methods; telehealth PrEP
Mesh:
Substances:
Year: 2020 PMID: 32323593 PMCID: PMC7180299 DOI: 10.1177/2325958220919269
Source DB: PubMed Journal: J Int Assoc Provid AIDS Care ISSN: 2325-9574
Participant Demographics.
| Demographic | Overall | Requester (n = 10) | Current (n = 21) |
|---|---|---|---|
| Sex | |||
| Female | 5 | 5 | 0 |
| Male | 26 | 5 | 21 |
| Transgender | 0 | 0 | 0 |
| Race/ethnicity | |||
| White (non-Hispanic) | 10 | 3 | 7 |
| Black (non-Hispanic) | 5 | 2 | 3 |
| American Indian or Alaskan Native | 0 | 0 | 0 |
| Asian or Pacific Islander | 3 | 1 | 2 |
| Hispanic or Latino | 9 | 4 | 5 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| More than one race | 4 | 0 | 4 |
| Age | |||
| 18-29 | 23 | 9 | 14 |
| 30-39 | 7 | 1 | 6 |
| 40-49 | 0 | 0 | |
| 50-59 | 0 | 0 | |
| 60-64 | 1 | 1 | |
| Insurance | |||
| Uninsured | 1 | 1 | 0 |
| Medicaid | 8 | 2 | 6 |
| Parents (unspecified) | 5 | 2 | 3 |
| Employer based | 11 | 2 | 9 |
| Kaiser | 4 | 3 | 1 |
| ACA plan | 2 | 0 | 2 |
| Duration on PrEP | |||
| Not yet | 12 | 10 | 2a |
| Less than 6 months | 9 | 0 | 9 |
| One year or more | 7 | 0 | 7 |
| Three years or more | 3 | 0 | 3 |
Abbreviations: PrEP, pre-exposure prophylaxis; ACA, Affordable Care Act.
a Medications were being shipped at time of interview.
Themes and Exemplary Quotes.
| Easy access to laboratories facilitates compliance with monitoring | There was one right around the corner from my house. (PT20, 24-year-old, African
American male) |
| Requirements create a helpful structure | Obviously it’s like a commitment, but I think it’s obviously—it’s for the
better. It’s actually kind of like, one of the—the draws, it’s like, having to
commit to a regimen almost. Or, like a schedule. (PT25, 27-year-old, White
male) |
| Results of laboratory work provide reassurance and underscore the benefits of the PrEP package. | I knew that, with the lab monitoring, if something were happening [eg, adverse
effects] that we would catch it and I could just discontinue the medication and I
would be fine. (PT13, 30-year-old, Latino male) |
| Problems with laboratories are minor annoyances | The only issue that I had is that I guess my name was shortened in their system.
So, they couldn’t find me initially. But then she just called tech services, and
they figured it out right away. It took, like, less than 5 minutes. In the
meantime, I had also messaged Nurx. And they got back to me really quickly. And
so, that was the only problem I had. Other than that, she had my insurance
already. She knew what lab she was supposed to do. I was in and out. (PT14,
26-year-old, Latino male) |
Abbreviation: PrEP, pre-exposure prophylaxis.
Key Recommendations to Encourage Laboratory Monitoring Compliance.
|
Explain the purpose of the frequency of monitoring to counteract concerns about the safety of the medication. Assess how patients feel about quarterly monitoring, rather than assuming it will be a burden. Proactively message patients about the subsidiary benefits/“perk” of quarterly testing, particularly for those who opt into the STI screening. Encourage patients to persevere through the “start-up syndrome” of all aspects of becoming a PrEP user including not only the possibility of experiencing short-term, physical side effects, and the necessity of building a routine around daily pill taking but also encourage the development of a routine around laboratory testing, that is, finding a laboratory and adjusting to the facility’s structure. Advise patients that laboratory monitoring requirements may not be easily fulfilled and can limit ongoing access to PrEP. Discuss potential strategies to overcome laboratory testing barriers such as home testing and/or alternative HIV prevention methods ahead of time. |
Abbreviation: PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.